BR112018071370A2 - composições farmacêuticas orais de mesalazina - Google Patents

composições farmacêuticas orais de mesalazina

Info

Publication number
BR112018071370A2
BR112018071370A2 BR112018071370A BR112018071370A BR112018071370A2 BR 112018071370 A2 BR112018071370 A2 BR 112018071370A2 BR 112018071370 A BR112018071370 A BR 112018071370A BR 112018071370 A BR112018071370 A BR 112018071370A BR 112018071370 A2 BR112018071370 A2 BR 112018071370A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
mesalazine
oral pharmaceutical
mesalazine oral
extended
Prior art date
Application number
BR112018071370A
Other languages
English (en)
Portuguese (pt)
Inventor
Chi Yeh Liang Alfred
Dingari Venkataramana
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112018071370A2 publication Critical patent/BR112018071370A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018071370A 2016-04-19 2017-04-18 composições farmacêuticas orais de mesalazina BR112018071370A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324416P 2016-04-19 2016-04-19
PCT/US2017/028067 WO2017184566A1 (en) 2016-04-19 2017-04-18 Oral pharmaceutical compositions of mesalazine

Publications (1)

Publication Number Publication Date
BR112018071370A2 true BR112018071370A2 (pt) 2019-02-05

Family

ID=59298513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071370A BR112018071370A2 (pt) 2016-04-19 2017-04-18 composições farmacêuticas orais de mesalazina

Country Status (13)

Country Link
US (2) US10874617B2 (enExample)
EP (1) EP3445340A1 (enExample)
JP (1) JP2019513800A (enExample)
KR (1) KR102381586B1 (enExample)
CN (1) CN109310642B (enExample)
AR (1) AR108231A1 (enExample)
AU (1) AU2017252410A1 (enExample)
BR (1) BR112018071370A2 (enExample)
CA (1) CA3021071A1 (enExample)
MX (1) MX387731B (enExample)
RU (1) RU2744576C2 (enExample)
TW (1) TW201740932A (enExample)
WO (1) WO2017184566A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
CA3021066C (en) 2016-04-19 2024-04-09 Ferring B.V. Oral pharmaceutical compositions of nicotinamide
TR201722039A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mesalazi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
CA3136081A1 (en) * 2019-05-03 2020-11-12 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US20210236519A1 (en) * 2020-01-30 2021-08-05 Atoz Pharmaceuticals Pvt Ltd Controlled release dosage forms of 5-aminosalicylic acid and process thereof
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof
EP4382099A1 (en) * 2022-12-05 2024-06-12 ADD Advanced Drug Delivery Technologies, Ltd. Drug loaded modified release pellets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ES2298236T3 (es) * 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
CA2746767A1 (en) 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Oral formulations
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CN102579388A (zh) * 2012-03-10 2012-07-18 吉林化工学院 美沙拉秦结肠定位给药缓释片的制备
WO2013144176A1 (en) 2012-03-30 2013-10-03 Laboratorios Del Dr. Esteve, S.A. Controlled release formulatin comprising mesalamine
CA2876540C (en) 2012-06-15 2022-11-29 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
US20140178468A1 (en) 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
US9763887B2 (en) * 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
ES2788866T3 (es) 2013-12-13 2020-10-23 Conaris Res Institute Ag Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida para su uso en influir beneficiosamente en los niveles de lípidos en sangre mediante la modificación de la microbiota intestinal
CA2932504A1 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
US20160045442A1 (en) * 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
CN104257669A (zh) 2014-09-25 2015-01-07 合肥平光制药有限公司 一种用于向肠道递送水杨酸类药物的口服给药组合物
CN105687158B (zh) * 2016-01-21 2019-06-07 贝沃特医药技术(上海)有限公司 一种时间依赖释放机制的美沙拉嗪微粒制剂及其制备方法

Also Published As

Publication number Publication date
US20190105275A1 (en) 2019-04-11
CN109310642A (zh) 2019-02-05
EP3445340A1 (en) 2019-02-27
RU2744576C2 (ru) 2021-03-11
CA3021071A1 (en) 2017-10-26
KR20180133503A (ko) 2018-12-14
US20210220281A1 (en) 2021-07-22
RU2018137359A (ru) 2020-05-19
US10874617B2 (en) 2020-12-29
CN109310642B (zh) 2021-07-20
MX387731B (es) 2025-03-18
KR102381586B1 (ko) 2022-04-04
MX2018012618A (es) 2019-06-24
WO2017184566A1 (en) 2017-10-26
AU2017252410A1 (en) 2018-11-01
AR108231A1 (es) 2018-08-01
TW201740932A (zh) 2017-12-01
RU2018137359A3 (enExample) 2020-07-03
JP2019513800A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
PH12016502552A1 (en) Formulation comprising a gemcitabine-prodrug
MA50541A (fr) Formulations pharmaceutiques
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
DK3634468T3 (da) Fast sammensætning til oral indgivelse
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EP3316685A4 (en) Lyophilized Pharmaceutical Compositions
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MA49837A (fr) Compositions pharmaceutiques
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (en) PHARMACEUTICAL FORMULATIONS
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
PL3157506T3 (pl) Kompozycja farmaceutyczna do podawania doustnego o maskowanym smaku
IL268708B (en) Pharmaceutical compositions for combination therapy
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
EP3651800A4 (en) HYPER COMPRESSED PHARMACEUTICAL FORMULATIONS
EP3706731A4 (en) IMPROVED DRUG FORMULATIONS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2771 DE 15-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.